Tvardi Therapeutics (TVRD) Shares Outstanding (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Shares Outstanding (Entity) of $9.4 million for Q1 2026, up 26.45% sequentially from $7.4 million in Q4 2025, and up 515.36% YoY from $1.5 million in Q1 2025.
Tvardi Therapeutics (TVRD) Shares Outstanding (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Shares Outstanding (Entity) for 14 years, with the latest figure at $9.4 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 515.36% year-over-year to $9.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.4 million (up 515.36% YoY) and the FY2025 annual result came in at $7.4 million, up 386.9% from the prior year.
- Shares Outstanding (Entity) improved to $9.4 million in Q1 2026 per TVRD's latest filing, from $7.4 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $9.4 million in Q1 2026 and troughed at $1.5 million in Q1 2022.
- A 5-year average of $3.2 million and a median of $1.5 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The widest YoY moves for Shares Outstanding (Entity): up 515.67% in 2025, down 0.4% in 2025.
- Over 5 years, Shares Outstanding (Entity) stood at $1.5 million in 2022, then increased by 1.27% to $1.5 million in 2023, then climbed by 0.69% to $1.5 million in 2024, then surged by 386.9% to $7.4 million in 2025, then climbed by 26.45% to $9.4 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $9.4 million, $7.4 million, and $9.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | 9.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.38 Mn |
| Dec 31, 2025 | 7.42 Mn |
| Sep 30, 2025 | 9.38 Mn |
| Jun 30, 2025 | 8.25 Mn |
| Mar 31, 2025 | 1.52 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | 1.52 Mn |
| Jun 30, 2024 | 1.52 Mn |
| Mar 31, 2024 | 1.52 Mn |
| Dec 31, 2023 | 1.50 Mn |
| Sep 30, 2023 | 1.51 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 1.49 Mn |
| Sep 30, 2022 | 1.49 Mn |
| Jun 30, 2022 | 1.49 Mn |
| Mar 31, 2022 | 1.49 Mn |
| Dec 31, 2021 | 1.41 Mn |
| Sep 30, 2021 | 1.39 Mn |
| Jun 30, 2021 | 1.39 Mn |